




SEVERE PET / IMMINENT ECLAMPSIA FLOWCHART

(Addendum to Hypertensive Disorders in Pregnancy Guideline)



Drug Names

Active Ingredient	Trade Names
Methyldopa	HyPoTone®
Nifedipine	Adalat®
Labetelol	Trandate®
Prazosin	Pratsiol®
Bethamethasone	Celestone® Soluspan® Betanoid®
Dexamethosone	Decasone® Dexona®
Carvidilol	Dilatrend® Carloc®
Phenytoin	Epanutin®
MgSO4	Magnesium Sulphate

Authorship

These guidelines were drafted by a clinical team from Mediclinic and were reviewed by a panel of experts from SASOG and the BetterObs clinical team. All attempts were made to ensure that the guidance provided is clinically safe, locally relevant and in line with current global and South African best practise. Succinctness was considered more important than comprehensiveness.

All guidelines must be used in conjunction with clinical evaluation and judgement; care must be individualised when appropriate. The writing team, reviewers and SASOG do not accept accountability for any untoward clinical, financial or other outcome related to the use of these documents. Comments are welcome and will be used at the time of next review.

Released on date: 2019 12 01

Disclaimer:

This document has been developed by interdisciplinary healthcare teams utilising the best available evidence and resources believed to be accurate and current at the time of release. They are intended to provide general advice and guidance on which to base clinical decisions. SASOG takes no responsibility for matters arising from changed circumstances or information that may have become available after issued. They must not be solely relied on or used as a substitute for assessing the individual needs of each patient.